Drug Trial Radar · NCT00131144
Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy
Last checked: Nov 19, 2026Latest source record: Nov 17, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
583
Actual
Start
Nov 1999
Primary completion
Dec 2005
Study completion Dec 2005
Sponsor
- Lead sponsor
- NovartisNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Aug 17, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The most common ocular disease in patients with diabetes, diabetic retinopathy, is present in approximately 40% of diabetic patients; about 8% of diabetic patients have vision threatening diabetic retinopathy. Although intensive control of blood glucose has been shown to reduce the development and progression of diabetic retinopathy, intensive control of glucose is usually not achieved in clinical practice.
Conditions
- Diabetic Retinopathy
Interventions
Octreotide Acetate in Microspheres 20 mgDrug
Octreotide Acetate in MicrospheresDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- time to progression of diabetic retinopathyTime frame: throughout study
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Novartis
East Hanover, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.